Flagship Pioneering, the Cambridge, Mass., venture capital firm, brought biotech startup Laronde out of stealth mode in May, launching it with $50 million after four years of secrecy.
It was the first time Laronde disclosed its technology: a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases. Now, three months after making its public debut, Laronde announced it has raised $440 million from investors.
Create a display name to comment
This name will appear with your comment